Skip to Content

Genetically Engineered Immune Cells Are Showing Promise in Fighting HIV

January 3, 2018

CAR-T therapy, a treatment that reprograms DNA of immune cells so they attack disease, has been shown to suppress or even eradicate HIV in lab monkeys.

How it works: As Stat explains, the engineered immune cells seek out and bind to the virus and are also themselves immune to HIV infection, allowing them to keep working.

But: The technique, published in PLoS One, was only tested in lab dishes and two animals. It’s also unclear how long the benefits may last. Given that CAR-T therapies have historically been very expensive, it would likely need to be an out-and-out cure to prove successful.

Backstory: We’ve explained how CAR-T shows huge promise in treating cancer, and many firms are already investing heavily in the hope that the technique will find broader application. That hope, this news suggests, may prove to be founded.

Deep Dive


These scientists used CRISPR to put an alligator gene into catfish

The resulting fish appear to be more resistant to disease and could improve commercial production—should they ever be approved.

Next up for CRISPR: Gene editing for the masses?

Last year, Verve Therapeutics started the first human trial of a CRISPR treatment that could benefit most people—a signal that gene editing may be ready to go mainstream.

CRISPR for high cholesterol: 10 Breakthrough Technologies 2023

New forms of the gene-editing tool could enable treatments for common diseases.

An ALS patient set a record for communicating via a brain implant: 62 words per minute

Brain interfaces could let paralyzed people speak at almost normal speeds.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at with a list of newsletters you’d like to receive.